Cancer Prevention Research Institute of Texas
57
16
28
27
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
3.5%
2 terminated/withdrawn out of 57 trials
93.1%
+6.6% vs industry average
4%
2 trials in Phase 3/4
22%
6 of 27 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (57)
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
Role: collaborator
A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)
Role: collaborator
GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
Role: collaborator
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
Role: collaborator
Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver Cirrhosis
Role: collaborator
Quitxt Mobile Text Messaging Cessation Research Study
Role: collaborator
Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
Role: collaborator
Cancer-related Fatigue and Its Biological Contributors in Adolescent and Young Adult Brain Tumor Survivors: Effects of a Tele-exercise Intervention
Role: collaborator
Development and Testing of a Patient-facing Educational Tool About Liver Cancer Prevention
Role: collaborator
Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer
Role: collaborator
Liver Cancer Prevention Randomized Control Trial
Role: collaborator
Throat and Other HPV-Related Cancers in Men: Identifying Them Early
Role: collaborator
Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma
Role: collaborator
A Randomized Trial of Maintenance Systemic Therapy After Radiation for Oligometastatic Renal Cell Carcinoma (ASTROs)
Role: collaborator
Phase 2 Study of TVB-2640 in KRAS Non-Small Cell Lung Carcinomas
Role: collaborator
Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy
Role: collaborator
Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells
Role: collaborator
Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)
Role: collaborator
Comparing Immune Response of 2 vs 3 HPV Doses (27-45 Years Old)
Role: collaborator
Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)
Role: collaborator